A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: A trial of the ECOG-ACRIN cancer research group (E1908)

American Journal of Hematology

Volumn 91, Issue 3, 2016, Pages 308-312

  Zent, Clive S ^a,c   Victoria Wang, Xin ^b   Ketterling, Rhett P ^c   Hanson, Curtis A ^c   Libby, Edward N ^d,m   Barrientos, Jacqueline C ^e   Call, Timothy G ^c   Chang, Julie E ^f   Liu, Jane J ^g   Calvo, Alejandro R ^h   Lazarus, Hillard M ⁱ   Rowe, Jacob M ^j   Luger, Selina M ^k   Litzow, Mark R ^c   Tallman, Martin S ^l,n  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e Northwell Health   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g Illinois Cancer Care   (United States)

^h KETTERING HEALTH NETWORK   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

^j RAMBAM MEDICAL CENTER   (Israel)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m UNIVERSITY OF NEW MEXICO   (United States)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; RITUXIMAB; TRIACYLGLYCEROL LIPASE; VALGANCICLOVIR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ANEMIA; ARTICLE; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FATALITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GERIATRIC DISORDER; HUMAN; HYPONATREMIA; LOW DRUG DOSE; LUNG INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; RASH; SERUM SICKNESS; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; TOOTH INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VERY ELDERLY; VIRUS LOAD; WEIGHT REDUCTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; RITUXIMAB;

EID: 84959096243     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24265     Document Type: Article

References (34)

1. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012. National Cancer Institute Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2012/; 2015. Accessed November 2015.
2. Keating MJ, O'brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088.
3. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
4. Taylor RP, Lindorfer MA. Analyses of CD20 Monoclonal Antibody-Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies. Mol Pharmacol 2014;86:485-491.
5. Golay J, Introna M. Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 2012;526:146-153.
6. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413-3415.
7. Nabhan C, Patton D, Gordon L, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004;45:2269-2273.
8. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008;113:2110-2118.
9. Zent CS, Wu W, Bowen DA, et al. Addition of GM-CSF does not improve response to early treatment of high risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma 2013;54:476-482.
10. Frankfurt O, Ma S, Gordon L, et al. Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes. Leuk Lymphoma 2014;1-9.
11. Zent CS, Call TG, Bowen DA, et al. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Leuk Lymphoma 2015;56:2373-2378.
12. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177:7435-7443.
13. Aue G, Lindorfer MA, Beum PV, et al. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2010;95:329-332.
14. Zent CS, Taylor RP, Lindorfer MA, et al. Chemoimmunotherapy for relapsed/refractory and progressive 17p13 deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am J Hematol 2014;89:757-765.
15. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
16. Muller-Hermelink HK, Catovsky D, Montserrat E, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Jaffe E, Harris N, Stein H, et al., editors. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. pp 127-130.
17. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111:5446-5456.
18. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974;27:365-375.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Herold T, Seiler T, Egensperger R, et al. Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:169-172.
21. Di Pauli F, Berger T, Walder A, et al. Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: case report and review of the literature. J Clin Virol 2014;60:424-427.
22. Isidoro L, Pires P, Rito L, et al. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep 2014;2014:
23. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-773.
24. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5553-5555.
25. Elter T, Vehreschild JJ, Gribben J, et al. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Annal Hematol 2009;88:121-132.
26. Ambrose LR, Morel AS, Warrens AN. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood 2009;114:3052-3055.
27. Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol 2010;47:180-186.
28. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus Chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101-1110.
29. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015;385:1873-1883.
30. Laurenti L, Innocenti I, Autore F, et al. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. Leuk Res 2015;39:1066-1070.
31. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280-3288.
32. Beum PV, Kennedy AD, Williams ME, et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006;176:2600 -2609.
33. Beurskens FJ, Lindorfer MA, Farooqui M, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012;188:3532-3541.
34. Baig NA, Taylor RP, Lindorfer MA, et al. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol 2014;192:1620-1629.